WO2004112851A1 - Compositions d'hydrogel comportant des enzymes - Google Patents

Compositions d'hydrogel comportant des enzymes Download PDF

Info

Publication number
WO2004112851A1
WO2004112851A1 PCT/GB2004/002696 GB2004002696W WO2004112851A1 WO 2004112851 A1 WO2004112851 A1 WO 2004112851A1 GB 2004002696 W GB2004002696 W GB 2004002696W WO 2004112851 A1 WO2004112851 A1 WO 2004112851A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogel
layer
wound
wound dressing
oxidase
Prior art date
Application number
PCT/GB2004/002696
Other languages
English (en)
Inventor
Simon Foster
Original Assignee
Johnson & Johnson Medical Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Medical Limited filed Critical Johnson & Johnson Medical Limited
Priority to EP04743047A priority Critical patent/EP1635884A1/fr
Publication of WO2004112851A1 publication Critical patent/WO2004112851A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive plasters or dressings
    • A61F13/0203—Adhesive plasters or dressings having a fluid handling member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes

Definitions

  • the present invention relates to hydrogel compositions comprising active enzymes.
  • the invention also relates to methods of manufacture of such compositions, and the use of such compositions in wound dressings.
  • Hydrogel wound dressings in which the wound contacting layer comprises a hydrogel, are advantageous because wound exudate does not generally dry and consolidate with hydrogel. Consequently, the removal of a hydrogel dressing is usually neither painful nor detrimental to the healing process. Hydrogel dressings are particularly desirable for the treatment of burns. There can be difficulties in handling the structurally weak gels in high speed manufacturing processes, and in clinical practice. For this reason, the hydrogel layer may be laminated to a support layer, for example a plastic film or a textile layer.
  • the natural hydrogels include gelatins, pectins, and hyaluronic acid and its derivatives.
  • Semi-synthetic hydrogels include modified celluloses and modified starches.
  • Synthetic hydrogel- forming polymers suitable for use in wound dressings include certain polyurethanes, polyacrylates, polyacrylamides, and polyvinylpyrrolidones. Synthetic hydrogels have the advantage that they can be prepared as a liquid prepolymerisation mixture of controlled viscosity that can be applied to a suitable substrate, and then polymerised on the substrate to provide a desired hydrogel laminate.
  • US-A-5160328 describes a dressing having a wound contacting layer of a polyurethane hydrogel.
  • the polyurethane gel comprises from 0% to 90% of polyhydric alcohol such as polypropylene glycol, from 6% to 60% by weight of an isocyanate-terminated prepolymer, from 4% to 40% by weight of a polyethylene oxide based diamine, and the balance water.
  • the hydrogel layer is disposed on a support layer that provides mechanical support for the relatively weak hydrogel.
  • EP-A-0610056 describes a hydrogel dressing comprising a wound contacting layer of polyvinylpyrrolidone, which has been cross-linked by irradiation, and which is applied to a substrate.
  • the hydrogel facing surface of the substrate comprises fibers projecting into the hydrogel.
  • the hydrogel is cross-linked on the substrate and thereby firmly anchored thereto.
  • WOOO/07638 describes polyacrylate hydrogel materials suitable for use as the wound contacting layer of wound dressings.
  • WO02/38097 describes wound dressings having a layer of hydrogel coated onto the wound facing layer of an apertured polymer film support sheet.
  • WO97/02811 describes a hydrogel patch for the measurement of blood glucose.
  • the glucose drawn into the patch undergoes a reaction with a glucose oxidase in the gel, and the hydrogen peroxide thereby released is used for electrochemical determination of the glucose concentration.
  • the preferred gel is a cross-linked polyethylene oxide.
  • the cross-linking can be carried out with a bis acrylamide in the presence of the glucose oxidase.
  • US-A-5648252 describes incorporating enzymes into insoluble hydrogels formed by combining an anionic hydrogel with a cationic hydrogel.
  • WO00/78332 describes incorporating fish serine proteases into medicinal compositions, including gels.
  • the present invention provides a wound dressing comprising a synthetic hydrogel material, wherein an active enzyme is dispersed in the synthetic hydrogel material.
  • the wound dressing of the present invention further comprises a support and the synthetic hydrogel material containing the dispersed active enzyme is coated onto the support.
  • the present invention provides a method of making a wound dressing comprising the steps of: preparing a hydrogel premix comprising a synthetic hydrogel polymer precursor and an enzyme; followed by polymerising the premix to produce a synthetic hydrogel material having an active enzyme dispersed therein.
  • the method further comprises applying a layer of the premix to a solid support; and the step of polymerising the premix is carried out on the support to produce a layer of the synthetic hydrogel material containing an active enzyme on the support.
  • the present invention further provides the use of a wound dressing according to the present invention for the preparation of a dressing for application to a wound.
  • the present invention provides a method of treatment of a wound comprising the step of applying a wound dressing in accordance with the present invention to the surface of the wound
  • the Support may be any structure having stiffness or tensile strength greater than that of the hydrogel layer.
  • the support is in the form of a sheet material, usually a flat sheet material.
  • the support is made from a material that is not water soluble or water swellable.
  • the support sheet may be formed from a thermoplastic film-forming polymer.
  • the polymer is conformable but not substantially elastomeric.
  • Suitable polymers include, but are not limited to, polyolefins such as polyethylene and polypropylene; polyesters; polyamides such as nylons; fluoropolymers such as polyvinylidene fluoride (PVDF) or polytetrafluoroethylene (PTFE); olefin copolymers such as ethylene vinyl alcohol (EVA), and mixtures and laminates thereof.
  • the film has a thickness by weight (ASTM E252-84) of from 10 to 200 micrometers, more preferably from 25 to 100 micrometers.
  • the support may be continuous or interrupted.
  • the support sheet may be a polymer film, which may be apertured to provide liquid permeability.
  • the support sheet may comprise, or consist essentially of, a woven, nonwoven or knitted fabric.
  • the support sheet is adapted to block or restrict passage of liquid from a back surface to a wound facing surface of the support sheet. That is to say, the support sheet allows fluid to pass through the support sheet from the wound site, but blocks or restricts flow of the fluid back through the support sheet onto the wound (also known as wet-back).
  • Such non-wetting support sheets may for example be made from porous non-woven fabrics comprising a layer of hydrophobic fibers, or having a hydrophobic finish applied to at least the outer surface thereof.
  • the support sheet has greater liquid permeability to the flow of liquid away from the wound facing surface than to the flow of liquid towards the wound facing surface.
  • the support sheet is formed from a substantially liquid-impermeable sheet material provided with tapered capillaries, each capillary having a base substantially in the plane of the wound facing surface of the support sheet and an apical opening remote from the wound facing surface of the support sheet and preferably in contact with the hydrogel and/or the absorbent layer.
  • the conical capillaries provide rapid one-way wicking of fluid from the front of the support sheet, with minimal wet-back.
  • Support sheets of this type are described in GB-A-1526778, the entire content of which is incorporated herein by reference. Support sheets of this type may be manufactured, for example, by embossing or vacuum perforation of a liquid-impermeable thermoplastic film.
  • the density of the capillaries is from 10 to 400 per cm 2 , more preferably from 50 to 200 per cm 2 .
  • the open area of the support sheet is from 5 to 50% of the total area, more preferably from 10 to 25% of the total area.
  • enzyme refers to a polypeptide having catalytic effect in a metabolic reaction. It encompasses both therapeutic enzymes and diagnostic enzymes, but it does not encompass growth factors.
  • Suitable enzymes may be selected from the group consisting of:
  • antimicrobial enzymes such as lysozyme
  • oxidase enzymes such as lactate oxidase, glucose oxidase, hexose oxidase, cholesterol oxidase, galactose oxidase, pyranose oxidase, choline oxidase, pyruvate oxidase, oxalate oxidase, glycollate oxidase and D-aminoacid oxidases;
  • peroxidase enzymes such as lactoperoxidase, horseradish peroxidase, iodide peroxidase, chloride peroxidase and myeloperoxidase;
  • Matrix forming and degrading enzymes including proteinases and proteases, for example Streptokinase, collagenase and streptodornase , bromelain, plasmin and trypsin, Urokinase, plasmin, brinolase, tissue plasminogen activator, Factor Xllla, thrombin, Von Willibrand factor,
  • Metabolic enzymes for example Hexokinase, Phosphoglucose isomerase, phosphofructokinase, Aldose, Triose, phosphate isomerase, glyceraldehydes 3- phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerol mutase, enolase, pyruvate kinase, Citrate synthase, Aconitase, Isocitrate lyase, malate synthase, malate dehydrogenase;
  • the enzymes comprise lactate oxidase, for the following reasons.
  • Oxygen is a prerequisite for the formation of chemical energy within living cells.
  • the tissue will preferentially use the glycolytic pathway to generate energy in the form of adenosine triphosphate (ATP), since the amount of oxygen is limiting.
  • ATP adenosine triphosphate
  • Pyruvate is converted to lactate by lactate dehydrogenase, in the process generating two molecules of ATP per molecule of pyruvate hydrolysed.
  • lactate dehydrogenase in the process generating two molecules of ATP per molecule of pyruvate hydrolysed.
  • only a small fraction of the potential energy content of glucose is released by anaerobic conversion into lactate; much more energy can be released by the oxidative decarboxylation of pyruvate via the citric acid cycle.
  • Lactate is in effect a metabolic "dead-end" in the mammalian body, as it must be converted back into pyruvate before it can be metabolised. In mammals, this reaction is only performed in the liver. Consequently, in wounds, lactate concentrations often rise to levels which are detrimental to the healing process. In particular, the presence of large amount of lactic acid in the wound causes a severe drop in the pH of the wound and thus slows down the healing process; (the ideal pH for the healing process to take place in the wound is thought to be around 6.0). In addition, high levels of lactic acid upset the redox balance of the wound, and impair metabolic balance in other ways.
  • the activity of the dressings can be specified in terms of activity units per gram of the dressing.
  • One unit will remove 1.0 ⁇ mol of L-lactate per minute at pH6.5 at 37°C.
  • one unit of lactate oxidase activity is the amount needed to oxidize 1.0 ⁇ mol of L-lactate to pyruvate and H 2 O 2 per minute at pH6.5 at 37°C.
  • the activity (e.g. lactate oxidase activity) of the dressings is from about 0.001 units/g to about 100 units/g, more preferably from about 0.01 units/g to about 10 units/g, and most preferably from about 0.1 units/g to about 1 unit/g.
  • the compound or reagent comprises a lactate oxidase enzyme.
  • Lactate oxidase may be derived from any organism or may be partially or wholly synthetic. Suitable lactate oxidase species are present in both prokaryotes and eukaryotes. From the point of view of expense, prokaryote-derived enzymes will be preferred, although eukaryote enzymes, preferably mammalian or human, are less likely to cause immunogenic reactions in the wound site. Human lactate oxidase is most preferable.
  • each gram of the dressings according to the present invention contains from about 0.1 ng to about 1mg of lactate oxidase, more preferably from about 1ng to about 100ng of lactate oxidase.
  • Lactate oxidase enzyme that have been engineered to possess advantageous properties over the wild type species may also be used according to the present invention.
  • enzymes may be modified by site-directed mutagenesis to accelerate the rate at which they metabolise lactate or to reduce the immunogenicity of the protein.
  • Lactate oxidase acts to catalytically convert lactic acid into pyruvic acid that will diffuse into the environment of the wound, where it may be utilised as an energy source by the cells of the wound through its oxidative carboxylation as part of the citric acid cycle.
  • the availability of this extra energy source will allow the cells of the wound to grow more quickly.
  • the pH of the wound environment will increase as the lactic acid concentration in the wound falls.
  • the oxygen needed for lactate oxidase reaction comes from the environment of the wound and from the atmosphere itself.
  • the hydrogen peroxide generated as a by-product of this reaction of lactate oxidase with oxygen may spontaneously decompose to release oxygen back into the wound.
  • the hydrogen peroxide may also be beneficial to the wound healing process.
  • hydrogen peroxide is a bactericidal agent, acting to inhibit the growth of microbes on the wound surface, thereby minimising the risk of development of clinical infections in the wound.
  • this chemical acts to minimise the build-up of chemical odours developing from microbial growth in the wound.
  • the higher the lactate concentration in the wound the greater the activity of lactate oxidase in the wound dressing or implant that will result. Consequently, the system is self-regulating.
  • Additional compounds may also be coupled in particular to the oxidase enzymes used in of the present invention.
  • a compound can be used that accelerates the reduction of H 2 O 2 into H 2 O and molecular oxygen.
  • a suitable enzyme that catalyses this process is the catalase enzyme. The reaction in the presence of lactate oxidase and catalase is set out below.
  • catalase as a coupled enzyme has the advantage that local oxygen levels in the wound environment may be boosted, causing a concomitant increase in growth of cells in the environment of the wound.
  • Catalase enzyme may be obtained from any source, as discussed above for lactate oxidase.
  • Potato homogenate is a particularly good source of catalase.
  • Catalase activity is generally defined such that one unit will decompose 1.O ⁇ mol of H 2 O 2 per minute at pH 7.0 at 25°C, while the H 2 O 2 concentration falls from 10.3 to 9.2mM.
  • the catalase activity per gram of the wound dressings of the present invention is within one of the preferred ranges specified above for the lactate oxidase activity-
  • the activity of commercially available catalase varies from about 1000 units/mg to about 50,000 units/mg. It follows that the amount of catalase used to make the wound dressings of the invention is preferably about 0.01 ng to about 10ng/gram of the hydrogel dry weight.
  • Indicator systems that are responsive to the concentration of various substances such as hydrogen peroxide in a wound may also be associated with the wound dressing or implant of the present invention.
  • the indicated concentration of H 2 O 2 produced by the reaction between lactate oxidase and lactic acid gives an indication of the concentration of lactate initially present in the wound environment. This will give a physician useful information about the metabolic condition of the wound, for example an indication of the degree of hypoxia.
  • the indicator systems may comprise a redox indicator compound, which is usually activated by a peroxidase enzyme in the presence of hydrogen peroxide.
  • the indicator compound is a chromogenic compound.
  • Suitable chromogenic substrates suitable as coupled indicators of lactate concentration include the following, along with the colour produced upon oxidation by H 2 O 2 .
  • ABTS (2,2'-azino-bis-(3-ethyibenzthiazoline- ⁇ -sulphonic acid) [green]; OPD (o- phenylened ⁇ amine) [orange]; TMB (3,3'-5,5'-tetramethylbenzidine) [blue]; O- dianisidine [orange]; 5AS (5-aminosalicylic acid) [brown]; DAB (3,3'- diaminobenz ⁇ dine) [brown]; AEC (3-amino-9-ethylcarbazole) [blue]; 4C1 N (4- chloro-l-naphthol) [blue]. All of these indicator compounds are available from Sigma Chemical Company.
  • a means of oxidation of the compound must also be present in the dressing or implant. Any means of oxidation may be used that can be coupled stoichiometrically to the amount of hydrogen peroxide present in the wound.
  • a peroxidase enzyme may be incorporated into the device, so causing the oxidation of an indicator compound. This reaction is shown below:
  • the means of oxidation of the indicator compound comprises a peroxidase enzyme, more preferably horseradish peroxidase. Suitable concentrations of peroxidase enzyme and indicator can readily be determined by the person skilled in the art.
  • hydrogel layer refers to thin, two-dimensional layer, preferably consisting essentially of the hydrogel composition. It may be a substantially unitary layer, and it may have substantially constant thickness. In certain embodiments, the hydrogel layer is coextensive with the support. The advantages of the invention can be achieved with a thin hydrogel layer, which minimises the cost of the dressing.
  • the hydrogel layer typically has a dry basis weight of from about 1 to about 2000g/m 2 , for example about 5 to about 1000 g/m 2 , or from 10 about to about 500g/m 2 , or from about 10 to about 200g/m 2 , or from about 10 to about 100g/m 2 , or from 10 about to about 50g/m 2 .
  • the hydrogel layer may be continuous or discontinuous. Continuous hydrogel layers extend over and cover any apertures in the support. Such continuous layers provide the advantage of temporarily blocking (gel blocking) the passage of wound fluid through the support until the hydrogel is saturated. This helps to prevent drying out of wounds having low rates of exudate production.
  • the hydrogel layer is apertured. In some embodiments it is apertured in register with apertures in the support so as not to obstruct passage of fluid through the support even when the hydrogel is fully swelled. In these embodiments, there is substantially no hydrogel initially present in or covering the apertures of the support.
  • hydrogel refers generally to materials that interact with wound fluid under physiological conditions to form a hydrated gel at the wound surface. That is to say, the hydrogel polymer forms a gel with water under physiological conditions of temperature and pH. Such hydrogel layers are formed by medically acceptable synthetic macromolecular materials that have the ability to swell and absorb fluid while maintaining a strong integral structure.
  • the hydrogel material is normally substantially insoluble in water under physiological conditions, whereby the hydrogel is not washed away by the wound fluid.
  • the hydrogel may be may be bioabsorbable. That is to say, it may undergo full degradation and resorption in vivo in the mammalian body.
  • a suitable composition for the hydrogel layers of the present invention comprises a plasticised three-dimensional matrix of cross-linked polymer molecules. Such polymers can have sufficient structural integrity to be self-supporting even at very high levels of internal water content, with sufficient flexibility to conform to the surface contours of the human skin.
  • Exemplary insoluble gels include polyurethane gels, certain cross-linked polyacrylate gels, and gels formed by polymerizing vinyl alcohols, vinyl esters, vinyl ethers, N-vinyl pyrrolidone, PLURONIC (Registered Trade Mark) (block polyethylene glycol, block polypropylene glycol) polystyrene-, maleic acid, and mixtures thereof.
  • polyurethane herein refers to a polymer having a plurality (preferably at least 10, 20 or 100) urethane and/or urea linkages in the main polymer chain.
  • polyacrylate herein refers to a polymer wherein the main polymer chain is formed by polymerising or copolymerising one or more carboxy vinyl monomers (acrylates or acrylate derivatives), for example one or more monomers selected from the group consisting of meth(acrylic) acid, acrylamide, N-substituted acrylamides, acylamidopropane sulphonic acid, NN- dimethylacrylamide diacetone acrylamide, acryloyl morpholine, and mixtures thereof.
  • carboxy vinyl monomers acrylates or acrylate derivatives
  • the gel adheres strongly to the surface of the support material to resist washing off by wound fluid.
  • the gel may be directly coated or chemically covalently bonded to the support material.
  • the hydrogel layer comprises a hydrogel material selected from polyurethane gels, and polyacrylates, i.e. polymers of acrylates and acrylate derivatives such as modified acrylamides and mixtures thereof.
  • the gel- forming polymer of the hydrogel layer consists essentially of polyurethane or polyacrylate
  • the hydrogel layer comprises a hydrogel material of the kind described in WOOO/07638 or WO00/065143, the entire contents of which are incorporated herein by reference.
  • the gels are cross-linked, and the cross-linking may be either covalent or ionic.
  • the hydrogel material further comprises from 5 to 50% by weight on a dry weight basis of one or more humectants such as glycerol.
  • the hydrogel composition used in the present invention typically consists essentially of a cross-linked hydrophilic polymer of a hydrophilic monomer and optionally one or more comonomers, together with water and/or one or more organic plasticisers, and optionally together with one or more additives selected from surfactants, polymers, pH regulators, bioactive compounds and mixtures thereof, with less than about 10% by weight of other additives.
  • the hydrophilic acrylate monomer may be one or more ionic monomers.
  • the hydrophilic monomer may be a mixture of anionic and cationic monomers, typically in substantially equimolar amounts.
  • the one or more ionic monomers may for example be selected from: 2-acrylamido-2-methylpropane sulphonic acid or an analog thereof or one of its salts (e.g. an ammonium or alkali metal salt such as a sodium, potassium or lithium salts); acrylic acid or an analogue thereof or one of its salts (e.g. an alkali metal salt such as a sodium, potassium or lithium salt); and/or a polymerisable sulphonate or a salt thereof (e.g.
  • an alkali metal salt such as a sodium, potassium or lithium salt
  • acrylic acid 3-sulphopropyl ester or an analogue thereof, or a salt thereof.
  • analogue in this context refers particularly to substituted derivatives of 2- acrylamido-2-methylpropane sulphonic acid, of acrylic acid or of acrylic acid (3- sulphopropyl) ester.
  • a particularly suitable ionic monomer is a sodium salt of 2-acrylamido-2- methylpropane sulphonic acid, commonly known as NaAMPS and/or acrylic acid (3-sulphopropyl) ester potassium salt, commonly known as SPA or SPAK.
  • the hydrophilic acrylate monomer may alternatively or additionally be non-ionic, for example it may be selected from acrylamide or a mono- or di-N-alkylacrylamide or an analog thereof.
  • non-ionic water soluble monomers containing an alkyl or substituted alkyl group linked to a carbon-carbon double bond via an amido or alkylamido (-CO.NH- or -CO.NR-) function.
  • Examples of such analogs include diacetone acrylamide (N-1,1- dimethyl-3-oxobutyl-acrylamide), vinyl lactams, N-alkylated acrylamides, N,N- dialkylated acrylamides, N-vinyl pyrrolidone, N-acryloyl morphoiine and any mixture thereof, particularly N-acryloyl morphoiine.
  • cross-linking agents are suitably used to provide the necessary mechanical stability and insolubility to the hydrogel.
  • the amount of cross-linking agent required will suitably from about 0.01% to about 0.5%, particularly from about 0.05% to about 0.4%, most particularly from about 0.08% to about 0.3%, by weight of the total polymerisation reaction mixture.
  • Typical cross-linkers for use in cross-linking of polyacrylates useful in the present invention include tripropylene glycol diacrylate, ethylene glycol dimethacrylate, triacrylate, polyethylene glycol diacrylate (polyethylene glycol (PEG) molecular weight between about 100 and about 4000, for example PEG400 or PEG600), and methylene bis acrylamide.
  • the one or more organic plasticisers when present, may suitably comprise any of the following either alone or in combination: at least one polyhydric alcohol (such as glycerol, polyethylene glycol, or sorbitol), at least one ester derived therefrom, at least one polymeric alcohol (such as polyethylene oxide) and/or at least one mono- or poly-alkylated derivative of a polyhydric or polymeric alcohol (such as alkylated polyethylene glycol).
  • Glycerol is the preferred plasticiser.
  • An alternative preferred plasticiser is the ester derived from boric acid and glycerol.
  • the organic plasticiser may comprise up to about 45% by weight of the hydrogel composition.
  • the hydrogel compositions may comprise Non-ionic Surfactants, Anionic Surfactants, Cationic Surfactants, or mixtures thereof.
  • the total amount of surfactant, if present, is suitably up to about 10% by weight of the hydrogel composition, preferably from about 0.05% to about 4% by weight.
  • the hydrogel may be a polyurethane gel, for example a gel formed by reaction of an isocyanate prepolymer with a chain extending compound such as a diamine or water.
  • the hydrogel material may be formed from an aqueous mixture including from about 0% to about 90% by weight polyhydric alcohol; from about 6% to about 60% by weight aliphatic diisocyanate- terminated prepolymer; from about 4% to about 40% by weight polyethylene oxide-based polyamine; up to about 2% by weight sodium chloride; and the balance water.
  • a more suitable hydrogel composition for forming the polyurethane hydrogel layer comprises from about 15% to about 30% by weight of a polyhydric alcohol selected from a group consisting of polypropylene glycol, polyethylene glycol and glycerine, from about 8% to about 14% by weight isophorone- diisocyanate-terminated prepolymer, from about 5% to about 10% by weight polyethylene oxide-based diamine, up to about 1% by weight of a salt, and the remaining percentage water.
  • Suitable isocyanate capped prepolymers for the production of polyurethane hydrogels, and methods of manufacture thereof are described in EP-A-0335669 and WO9902587, the entire contents of which are incorporated herein by reference.
  • the hydrogel composition used in the present invention may include one or more additional ingredients, which may be added to the pre-polymerisation mixture or the polymerised product.
  • additional ingredients are selected from the group consisting of water, organic plasticisers, surfactants, polymers, pH regulators, colorants and mixtures thereof.
  • the polymers can for example be biopolymers, such as gelatin, pectin or hyaluronic acid.
  • the enzyme may be covalently bonded to the polymer chain of the synthetic hydrogel material.
  • the enzyme is frequently partially or completely copolymerized with the synthetic hydrogel material.
  • the hydrogel layer may be provided on the wound facing surface of the wound dressing according to the present invention.
  • the hydrogel then provides a wound friendly, soft, non-adherent and therapeutic wound contacting surface to the dressing.
  • the hydrogel layer is provided on the back surface of the support sheet, opposite the wound facing surface.
  • the dressing may further comprise a backing layer over the back face of the support sheet.
  • the backing layer supports the support sheet and any optional intermediate absorbent layer and suitably provides a barrier to passage of microorganisms through the dressing.
  • the backing layer may extend beyond at least one edge of the hydrogel layer to provide an adhesive-coated margin adjacent to the said edge for adhering the dressing to a surface, such as to the skin of a patient adjacent to the wound being treated.
  • An adhesive-coated margin may extend around all sides of the hydrogel layer, so that the dressing is a so- called island dressing. However, it is not necessary for there to be any adhesive- coated margin.
  • the backing layer is normally substantially liquid-impermeable.
  • the backing sheet is preferably semipermeable. That is to say, the backing sheet is preferably permeable to water vapour, but not permeable to liquid water or wound exudate.
  • the backing sheet is also microorganism-impermeable.
  • Suitable continuous conformable backing sheets will preferably have a moisture vapor transmission rate (MVTR) of the backing sheet alone of 300 to 5000 g/m 2 /24hrs, preferably 500 to 2000 g/m 2 /24hrs at 37.5"C at 100% to 10% relative humidity difference.
  • the backing sheet thickness is preferably in the range of 10 to 1000 micrometers, more preferably 100 to 500 micrometers.
  • the MVTR of the dressing according to the present invention as a whole is lower than that of the backing sheet alone, because the hydrogel layer and support sheet partially obstruct moisture transfer through the dressing.
  • the MVTR of the dressing (measured across the island portion of the dressing) is from 20% to 80% of the MVTR of the backing sheet alone, more preferably from 20% to 60% thereof, and most preferably about 40% thereof. It has been found that such moisture vapor transmission rates allow the wound under the dressing to heal under moist conditions without causing the skin surrounding the wound to macerate.
  • Suitable polymers for forming the backing sheet include polyurethanes and poly alkoxyalkyl acrylates and methacrylates such as those disclosed in GB-A- 1280631.
  • the backing sheet comprises a continuous layer of a high density blocked polyurethane foam that is predominantly closed-cell.
  • a suitable backing sheet material is the polyurethane film available under the Registered Trade Mark ESTANE 5714F.
  • the adhesive (where present) layer should be moisture vapor transmitting and/or patterned to allow passage of water vapor therethrough.
  • the adhesive layer is preferably a continuous moisture vapor transmitting, pressure-sensitive adhesive layer of the type conventionally used for island-type wound dressings, for example, a pressure sensitive adhesive based on acrylate ester copolymers, polyvinyl ethyl ether and polyurethane as described for example in GB-A-1280631.
  • the basis weight of the adhesive layer is preferably 20 to 250 g/m 2 , and more preferably 50 to 150 g/m 2 . Polyurethane-based pressure sensitive adhesives are preferred.
  • the area of the optional absorbent layer is typically in the range of from 1cm 2 to 200cm 2 , more preferably from 4cm 2 to 100cm 2 .
  • the optional absorbent layer may be any of the layers conventionally used for absorbing wound fluids, serum or blood in the wound healing art, including foams, sponges, gauzes, and nonwoven fabrics, and combinations thereof. Superabsorbents or hydrogels may be dispersed in the optional absorbent layer to improve liquid absorbency and retention.
  • the absorbent layer comprises a layer of absorbent foam, such as an open celled hydrophilic polyurethane foam prepared in accordance with EP-A-0541391, the entire content of which is expressly incorporated herein by reference.
  • the absorbent layer may be a nonwoven fibrous web, for example a carded web of viscose staple fibers.
  • the basis weight of the absorbent layer may be in the range of 50-500g/m 2 , such as 100-400g/m 2 .
  • the uncompressed thickness of the absorbent layer may be in the range of from 0.5mm to 10mm, such as 1mm to 4mm.
  • the free (uncompressed) liquid absorbency measured for physiological saline may be in the range of 5 to 30 g/g at 25°C.
  • the optional absorbent layer is a separate layer from the hydrogel layer in the wound dressings according to the present invention.
  • the hydrogel layer and the optional absorbent layer are adjacent.
  • the multilayer wound dressing according to the invention further comprises one or more protective cover sheets over the support sheet and any exposed hydrogel and/or adhesive.
  • these may comprise one or more release-coated paper cover sheets.
  • the dressing according to the present invention is sterile and packaged in a microorganism-impermeable container.
  • the wound dressing or implant according to the present invention may also contain a medicament, in addition to the enzyme or enzymes entrapped in the hydrogel.
  • Suitable medicaments will be well known to those of skill in the art and include antiseptics, such as povidone iodine or silver sulfadiazine; antibiotics such as enthromycin, neomycin, bacitracin, gentamycin, framycetin, thyrotrycin, polymyxin B, gramicidin, fusidic acid, chloramphemicol, tetracycline and its derivatives, minocycline chlortetracycline, hydrochloride, meclocyclin, penicillin and its derivatives, ampicillin or a cephalosporin; steroidal anti-inflammatories such as hydrocortisone, betamethasone, dexamethasone, prednisolone, and their derivatives; non- steroidal anti-inflammatories such as indomethacin, ketoprof
  • the method method of making a wound dressing according to the present invention comprises the steps of: preparing a hydrogel premix comprising a synthetic hydrogel polymer precursor and an enzyme; applying a layer of the premix to a solid support; followed by polymerising the premix on the support to produce a layer of synthetic hydrogel material on the support, wherein an active enzyme is dispersed in the synthetic hydrogel material.
  • the hydrogel premix is UV-curable and the step of polymerizing comprises curing the hydrogel with ultraviolet light.
  • the hydrogels include the hydrogels based on ionic acrylate and acrylamide- derived monomers described in detail above. Suitable catalysts for the polymerisation may also be present.
  • the hydrogel premix comprises an isocyanate-capped prepolymer
  • said step of polymerising comprises allowing said prepolymer to react with a chain extending compound.
  • Suitable chain extending compounds include water, diols and polyols, and diamines and polyamines.
  • Suitable catalysts for the polymerisation may also be present.
  • the hydrogel premix layer may be applied by spraying or, preferably, by a printing or transfer process.
  • Apertures may be formed in the hydrogel layer for example by drilling with a hollow needle.
  • the apertures may be formed by casting the support sheet in a mold having an array of projections corresponding to the apertures, followed by peeling the hydrogel layer from the mold and applying it in register to the support sheet.
  • the hydrogel layer may be applied to an apertured substrate by the method of WO00/65143, the entire content of which is incorporated herein by reference. Specific embodiments of the present invention will now be described further, by way of example.
  • a hydrogel layer for a dressing according to the present invention is prepared from the following materials:
  • SPA 3-sulphylacrylate potassium salt
  • PBS Phosphate buffered Saline
  • the lactate oxidase was diluted in PBS with a dilution of 4 units/ml. This solution was stored at -20°C and defrosted when required.
  • Hydrogen peroxide (H 2 0 2 ) generation assays utilise the reaction of H 2 0 2 with ortho- phenylene diamine (OPDA) in the presence of horseradish peroxidase.
  • OPDA ortho- phenylene diamine
  • the reaction mixture is initially colourless, but develops a yellow colouring with the presence of H 2 0 2 . It was the development of this colour that was measured quantitatively using the UV spectrophotometer.
  • the method used trans-well plates with the hydrogel placed within the well; this was then lowered into a solution containing both the lactate and the assay solutions.
  • This trans-well plates suspend the hydrogel in the solution above a membrane, which allows the free passage of lactate into, and hydrogen peroxide out of, the hydrogel, along with the assay solutions.
  • the method also included three controls, one positive and two negative.
  • the negative controls were: a) the hydrogel, containing no lactate oxidase, with the lactate and assay solutions, and b) the lactate and assay solutions on their own.
  • the positive control used was the lactate and assay solution, but this time in conjunction with a sample of the lactate oxidase.
  • the lactate oxidase solution used was of equal mass and dilution to that of the lactate oxidase found in the hydrogel to allow direct comparison.
  • the test method comprised the following steps:
  • trans-well inserts were then returned to their appropriate wells, and 2 units/ml lactate-oxidase control solutions was pipetted into its wells.
  • Time point readings were taken using the UV spectrophotometer every half an hour, for the first two hours, and then every hour for the next three hours.

Abstract

La présente invention a trait à un pansement de plaies comportant une feuille de support et une couche d'un matériau d'hydrogel synthétique revêtue sur la feuille de support, une enzyme active étant dispersée dans le matériau d'hydrogel synthétique. L'hydrogel est, de préférence un polyacrylate ou un polyacrylamide, et l'enzyme est, de préférence la lactate oxydase. L'invention a également trait à des procédés de fabrication de tels pansements de plaies par l'application d'un mélange préalable d'hydrogel comportant un précurseur polymèrique d'hydrogel synthétique et une enzyme à un support solide, suivie de la polymérisation du mélange préalable sur le support.
PCT/GB2004/002696 2003-06-23 2004-06-23 Compositions d'hydrogel comportant des enzymes WO2004112851A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04743047A EP1635884A1 (fr) 2003-06-23 2004-06-23 Compositions d'hydrogel comportant des enzymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0314604.0 2003-06-23
GB0314604A GB2403146B (en) 2003-06-23 2003-06-23 Method of making a wound dressing comprising lactate oxidase

Publications (1)

Publication Number Publication Date
WO2004112851A1 true WO2004112851A1 (fr) 2004-12-29

Family

ID=27637162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002696 WO2004112851A1 (fr) 2003-06-23 2004-06-23 Compositions d'hydrogel comportant des enzymes

Country Status (3)

Country Link
EP (1) EP1635884A1 (fr)
GB (1) GB2403146B (fr)
WO (1) WO2004112851A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072783A1 (fr) * 2004-01-30 2005-08-11 Insense Limited Amelioration de pansements dermiques
WO2005072784A1 (fr) * 2004-01-30 2005-08-11 Insense Limited Pansements constitues d'hydrogels hydrates et d'enzymes
WO2005110503A1 (fr) * 2004-04-30 2005-11-24 Kimberly-Clark Worldwide, Inc. Produits absorbants traites a l'aide d'une enzyme liee
US7731954B2 (en) 2002-04-24 2010-06-08 Insense Limited Wound dressings comprising hydrated hydrogels and enzymes
US7927588B2 (en) 2003-06-09 2011-04-19 Archimed Llp Skin dressings containing oxidoreductase enzyme
TWI425959B (zh) * 2010-11-10 2014-02-11 私立中原大學 皮膚傷口癒合材料及其製造方法
CN112980003A (zh) * 2021-04-16 2021-06-18 中国药科大学 一种基于天然多糖型抗菌水凝胶、制备方法及用途
CN114470297A (zh) * 2021-12-20 2022-05-13 山西医科大学 一种糖触发响应型创伤快愈型敷料及其制备方法
CN115216132A (zh) * 2022-08-18 2022-10-21 常州大学 GOx@F68/F127抗菌水凝胶及其制备方法
US20230226251A1 (en) * 2022-01-17 2023-07-20 Boock Engineering LLC Wound care covering

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0609778D0 (en) * 2006-05-17 2006-06-28 Agt Sciences Ltd Delivery means
US8187984B2 (en) 2006-06-09 2012-05-29 Malden Mills Industries, Inc. Temperature responsive smart textile
US8389100B2 (en) 2006-08-29 2013-03-05 Mmi-Ipco, Llc Temperature responsive smart textile
JP2008057099A (ja) 2006-08-29 2008-03-13 Mmi-Ipco Llc 感温性スマートテキスタイル
JP2008057100A (ja) * 2006-08-29 2008-03-13 Mmi-Ipco Llc 感温性且つ感湿性のスマートテキスタイル
WO2008070893A1 (fr) * 2006-12-13 2008-06-19 Tgr Biosciences Pty Ltd Stimulation de la production de milieux extracellulaire avec des cellules fibroblastes et/ou stimulation de la migration de cellules fibroblastes dans un système biologique
EP2338529B1 (fr) * 2009-12-24 2013-05-29 Paul Hartmann AG Matrice d'hydrogel dotée de propriétés d'adhésion améliorées
EP2338528B1 (fr) * 2009-12-24 2013-05-29 Paul Hartmann AG Matrice d'hydrogel dotée d'une capacité d'absorption élevée pour des liquides
RU2438654C1 (ru) * 2010-09-16 2012-01-10 Федеральное Государственное Унитарное Предприятие Научно-Производственный Центр "Фармзащита" Гидрогелевая композиция для лечения ожогов
CN103446618B (zh) * 2013-09-16 2015-11-18 河南科高辐射化工科技有限公司 一种抗菌水凝胶伤口被覆膜及采用该被覆膜制成的创面贴
GB201509044D0 (en) 2015-05-27 2015-07-08 Systagenix Wound Man Ip Co Bv Composition
CN108676179B (zh) * 2018-05-17 2020-09-22 复旦大学 一种基于酶交联的聚乙二醇类化学水凝胶及其制备方法
CN109799528B (zh) * 2019-01-17 2022-08-19 中国辐射防护研究院 用于放射性污染金属浅层取样的氧化凝胶及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576817A (en) * 1984-06-07 1986-03-18 Laclede Professional Products, Inc. Enzymatic bandages and pads
DE4026153A1 (de) * 1990-08-17 1992-02-20 Sebapharma Gmbh & Co Wundverband
US5648252A (en) * 1994-03-22 1997-07-15 Israel Fiber Institute State Of Israel Ministry Of Industry And Trade Supported polyionic hydrogels containing biologically active material
WO2000065143A1 (fr) * 1999-04-23 2000-11-02 First Water Limited Procede de revetement d'un substrat perfore
US20020018802A1 (en) * 1998-03-27 2002-02-14 Wolfgang Meyer-Ingold Wound coverings for removal of interfering factors from wound fluid
WO2002038097A1 (fr) * 2000-11-13 2002-05-16 Johnson & Johnson Medical Limited Pansements avec couche d'hydrogels
WO2003090800A1 (fr) * 2002-04-24 2003-11-06 Insense Limited Pansements pour plaies comprenant des enzymes et des hydrogels hydrates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69630226T2 (de) * 1995-07-12 2004-08-05 Cygnus, Inc., Redwood City Hydrogelpflaster
JP2003502071A (ja) * 1999-06-18 2003-01-21 ブジャーナソン・ヨーン・ブラーギ 魚類セリンプロティナーゼ及びそれらの薬品及び化粧品への利用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576817A (en) * 1984-06-07 1986-03-18 Laclede Professional Products, Inc. Enzymatic bandages and pads
DE4026153A1 (de) * 1990-08-17 1992-02-20 Sebapharma Gmbh & Co Wundverband
US5648252A (en) * 1994-03-22 1997-07-15 Israel Fiber Institute State Of Israel Ministry Of Industry And Trade Supported polyionic hydrogels containing biologically active material
US20020018802A1 (en) * 1998-03-27 2002-02-14 Wolfgang Meyer-Ingold Wound coverings for removal of interfering factors from wound fluid
WO2000065143A1 (fr) * 1999-04-23 2000-11-02 First Water Limited Procede de revetement d'un substrat perfore
WO2002038097A1 (fr) * 2000-11-13 2002-05-16 Johnson & Johnson Medical Limited Pansements avec couche d'hydrogels
WO2003090800A1 (fr) * 2002-04-24 2003-11-06 Insense Limited Pansements pour plaies comprenant des enzymes et des hydrogels hydrates

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731954B2 (en) 2002-04-24 2010-06-08 Insense Limited Wound dressings comprising hydrated hydrogels and enzymes
US7927588B2 (en) 2003-06-09 2011-04-19 Archimed Llp Skin dressings containing oxidoreductase enzyme
WO2005072783A1 (fr) * 2004-01-30 2005-08-11 Insense Limited Amelioration de pansements dermiques
WO2005072784A1 (fr) * 2004-01-30 2005-08-11 Insense Limited Pansements constitues d'hydrogels hydrates et d'enzymes
WO2005110503A1 (fr) * 2004-04-30 2005-11-24 Kimberly-Clark Worldwide, Inc. Produits absorbants traites a l'aide d'une enzyme liee
US7928282B2 (en) 2004-04-30 2011-04-19 Kimberly-Clark Worldwide, Inc. Absorbent products with a linked enzyme treatment
TWI425959B (zh) * 2010-11-10 2014-02-11 私立中原大學 皮膚傷口癒合材料及其製造方法
CN112980003A (zh) * 2021-04-16 2021-06-18 中国药科大学 一种基于天然多糖型抗菌水凝胶、制备方法及用途
CN114470297A (zh) * 2021-12-20 2022-05-13 山西医科大学 一种糖触发响应型创伤快愈型敷料及其制备方法
US20230226251A1 (en) * 2022-01-17 2023-07-20 Boock Engineering LLC Wound care covering
CN115216132A (zh) * 2022-08-18 2022-10-21 常州大学 GOx@F68/F127抗菌水凝胶及其制备方法

Also Published As

Publication number Publication date
GB0314604D0 (en) 2003-07-30
GB2403146A (en) 2004-12-29
EP1635884A1 (fr) 2006-03-22
GB2403146B (en) 2007-07-11

Similar Documents

Publication Publication Date Title
WO2004112851A1 (fr) Compositions d'hydrogel comportant des enzymes
ES2915475T3 (es) Apósito para heridas
CA2931174C (fr) Pansement medical a emission de no comprenant un module de production deno et un module emetteur de rayonnement
US10688215B2 (en) Flexible hydrogel wound dressings
US8871992B2 (en) Multilayer compositions and dressings
US6592890B1 (en) Conveyance of anti-infective activity to wound dressings
JP5483365B2 (ja) 生体分子でコーティングされた減圧式ドレッシング材の改良
EP3068448B1 (fr) Composition multicouche
US7368128B2 (en) Controlled release dressing for enzymatic debridement of necrotic and non-viable tissue in a wound
AU2004244803B2 (en) Skin dressings containing oxidoreductase enzyme
US20050159695A1 (en) Controlled release therapeutic wound dressings
JP2007519696A (ja) 皮膚ドレッシングにおける、又は皮膚ドレッシングに関する改良
US20140249496A1 (en) Compositions for use as or in wound dressings
JP2004520096A (ja) ヒドロゲル創傷被覆材
US20110135726A1 (en) Hydrogel composites and wound dressings
JP2022523780A (ja) 抗菌ドレッシング、ドレッシング構成要素、及び方法
US10076586B2 (en) Wound dressings
WO2009019485A2 (fr) Pansement de blessure
GB2433205A (en) Wound dressing comprising a strong cation exchange resin
Turner Interactive dressings used in the management of human soft tissue injuries and their potential in veterinary practice
WO2022228979A1 (fr) Pansement médical comprenant une composition bactériostatique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004743047

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004743047

Country of ref document: EP